Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 0.57 |
| ▸ | CNR1 | P21554 | 3/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3761529 | 0.91 | CNR2 (0.55) | CNR2CNR1KCNH2 | |
| SCHEMBL4538925 | 0.91 | CNR2 (0.56) | CNR2CNR1KCNH2 | |
| SCHEMBL3762588 | 0.90 | CNR2 (0.54) | CNR2CNR1KCNH2 | |
| SCHEMBL3766693 | 0.90 | CNR2 (0.58) | CNR2CNR1KCNH2 | |
| SCHEMBL3767621 | 0.89 | CNR2 (0.55) | CNR2CNR1KCNH2 | |
| SCHEMBL3762574 | 0.88 | CNR2 (0.56) | CNR2CNR1KCNH2 | |
| SCHEMBL3764773 | 0.88 | CNR2 (0.53) | CNR2CNR1 | |
| SCHEMBL12998992 | 0.88 | CNR2 (0.53) | CNR2CNR1KCNH2 | |
| SCHEMBL3761428 | 0.88 | CNR2 (0.53) | CNR2CNR1KCNH2 | |
| SCHEMBL3761745 | 0.88 | CNR2 (0.58) | CNR2CNR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305140-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | ASTRAZENECA AB (SE) | 2010-12-02 | — | — | US | claimed |
| EP-2035409-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANATGONIST FOR THE CB1-RECEPTOR | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | claimed |
| WO-2007145563-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | claimed |
| US-20100305140-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | ASTRAZENECA AB (SE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305140-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | ASTRAZENECA AB (SE) | 2010-12-02 | — | — | US | disclosed |
| WO-2007145563-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305140-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | CNR1, CNR2, CCKAR | CNR2 2/4885CNR1 1/4885KCNH2 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.